Libo Zhang1, Paula Marrano, Sushil Kumar, Michael Leadley, Evelyn Elias, Paul Thorner, Sylvain Baruchel. 1. Authors' Affiliations: New Agent and Innovative Therapy Program; Department of Paediatric Laboratory Medicine; Division of Hematology and Oncology, Department of Paediatrics, The Hospital for Sick Children; and Institute of Medical Sciences, University of Toronto, Toronto, Canada.
Abstract
PURPOSE: To investigate the antitumor effect of nab-paclitaxel, an albumin-stabilized nanoparticle formulation of paclitaxel, on pediatric solid tumor models. EXPERIMENTAL DESIGN: A panel of three rhabdomyosarcoma, one osteosarcoma and seven neuroblastoma cell lines were exposed to increasing concentrations of nab-paclitaxel in vitro. Cell viability was evaluated using the Alamar Blue Assay. Antitumor effect was further assessed in vivo in NOD/SCID xenograft and metastatic neuroblastoma mouse models. Tumor sections were analyzed by immunohistochemistry for cleaved caspase-3 and phospho-histone H3. Plasma and intratumoral paclitaxel concentrations were measured by liquid chromatography-mass spectrometry. Ratio of intratumoral and plasma concentration was compared between nab-paclitaxel and paclitaxel treatment groups. RESULTS: Nab-paclitaxel displayed significant cytotoxicity against most pediatric solid tumor cell lines in vitro in a dose-dependent manner. In vivo, nab-paclitaxel showed antitumor activity in both rhabdomyosarcoma (RH4 and RD) and neuroblastoma [SK-N-BE(2) and CHLA-20] xenograft models. In the SK-N-BE(2) metastatic model, nab-paclitaxel treatment significantly extended animal survival compared with control (P < 0.01). Nab-paclitaxel treatment induced tumor cell-cycle arrest and apoptosis in vivo. In the RH4 model, increased local relapse-free intervals were observed with nab-paclitaxel treatment (37.7 ± 3.2 days) comparing with paclitaxel (13.6 ± 2.07 days). Local relapsed tumors following paclitaxel treatment proved to be paclitaxel-resistant and remained responsive to nab-paclitaxel. Mechanistically, a higher tumor/plasma paclitaxel drug ratio in favor of nab-paclitaxel was observed. CONCLUSIONS: Nab-paclitaxel showed significant antitumor activity against all pediatric solid tumors associated with an enhanced drug intratumor delivery. Furthermore, testing of nab-paclitaxel in pediatric solid-tumor patient population is under development.
PURPOSE: To investigate the antitumor effect of nab-paclitaxel, an albumin-stabilized nanoparticle formulation of paclitaxel, on pediatric solid tumor models. EXPERIMENTAL DESIGN: A panel of three rhabdomyosarcoma, one osteosarcoma and seven neuroblastoma cell lines were exposed to increasing concentrations of nab-paclitaxel in vitro. Cell viability was evaluated using the Alamar Blue Assay. Antitumor effect was further assessed in vivo in NOD/SCID xenograft and metastatic neuroblastomamouse models. Tumor sections were analyzed by immunohistochemistry for cleaved caspase-3 and phospho-histone H3. Plasma and intratumoral paclitaxel concentrations were measured by liquid chromatography-mass spectrometry. Ratio of intratumoral and plasma concentration was compared between nab-paclitaxel and paclitaxel treatment groups. RESULTS:Nab-paclitaxel displayed significant cytotoxicity against most pediatric solid tumor cell lines in vitro in a dose-dependent manner. In vivo, nab-paclitaxel showed antitumor activity in both rhabdomyosarcoma (RH4 and RD) and neuroblastoma [SK-N-BE(2) and CHLA-20] xenograft models. In the SK-N-BE(2) metastatic model, nab-paclitaxel treatment significantly extended animal survival compared with control (P < 0.01). Nab-paclitaxel treatment induced tumor cell-cycle arrest and apoptosis in vivo. In the RH4 model, increased local relapse-free intervals were observed with nab-paclitaxel treatment (37.7 ± 3.2 days) comparing with paclitaxel (13.6 ± 2.07 days). Local relapsed tumors following paclitaxel treatment proved to be paclitaxel-resistant and remained responsive to nab-paclitaxel. Mechanistically, a higher tumor/plasma paclitaxel drug ratio in favor of nab-paclitaxel was observed. CONCLUSIONS:Nab-paclitaxel showed significant antitumor activity against all pediatric solid tumors associated with an enhanced drug intratumor delivery. Furthermore, testing of nab-paclitaxel in pediatric solid-tumorpatient population is under development.
Authors: Zhijian He; Anita Schulz; Xiaomeng Wan; Joshua Seitz; Herdis Bludau; Daria Y Alakhova; David B Darr; Charles M Perou; Rainer Jordan; Iwao Ojima; Alexander V Kabanov; Robert Luxenhofer Journal: J Control Release Date: 2015-02-26 Impact factor: 9.776
Authors: Peter J Houghton; Raushan T Kurmasheva; E Anders Kolb; Richard Gorlick; John M Maris; Jianrong Wu; Zeen Tong; Michael A Arnold; Moumita Chatterjee; Terence M Williams; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2015-03-23 Impact factor: 3.167
Authors: Bainan Wu; Si Wang; Surya K De; Elisa Barile; Bridget A Quinn; Irina Zharkikh; Angela Purves; John L Stebbins; Robert G Oshima; Paul B Fisher; Maurizio Pellecchia Journal: Chem Biol Date: 2015-07-09
Authors: Rebecca S Heist; Dan G Duda; Dushyant V Sahani; Marek Ancukiewicz; Panos Fidias; Lecia V Sequist; Jennifer S Temel; Alice T Shaw; Nathan A Pennell; Joel W Neal; Leena Gandhi; Thomas J Lynch; Jeffrey A Engelman; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2015-01-20 Impact factor: 11.205
Authors: C Patrick Reynolds; Min H Kang; John M Maris; E Anders Kolb; Richard Gorlick; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2015-07-07 Impact factor: 3.167
Authors: Joshua T Kowalczyk; Xiaolin Wan; Edjay R Hernandez; Ruibai Luo; Gaelyn C Lyons; Kelli M Wilson; Devorah C Gallardo; Kristine A Isanogle; Christina M Robinson; Arnulfo Mendoza; Christine M Heske; Jinqui-Qiu Chen; Xiaoling Luo; Alexander E Kelly; Simone Difilippantinio; Robert W Robey; Craig J Thomas; Dan L Sackett; Deborah K Morrison; Paul A Randazzo; Lisa M Miller Jenkins; Marielle E Yohe Journal: Mol Cancer Ther Date: 2020-11-06 Impact factor: 6.009